These studies highlight the potential for PSMA PET/CT to complement CT in diagnosing and managing RCC, particularly in detecting oligometastatic or oligoprogressive disease that could be amendable to metastasis-directed therapy. Here, FOLH1 is linked to renal cell carcinoma.